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sured by ELISA. Results: At every time point after baseline for each biomarker mea- 
sured, patients undergoing treatment with sertraline exhibited substantially less platelet 
activation than those receiving placebo. These differences reached statistical signifi- 
cance for PF4 (p=0.03), and bTG (p=0.04) at week 4, and for bTG (p=0.02), PECAM-t 
(p=0.01), and P-selectin (p=0.02) at week 16 after randomization. There was a trend 
towards inhibition of prostanoids (TxB2, and 6-keto-PGFla), and endothelial-released 
adhesion molecules (VCAM-1, and E-selectin) in patients treated with sertraline as well, 
although these changes were not significant. Conclusion: Despite aggressive anti*plate- 
let regimens including aspirin and clopidogret, treatment with sertraline in depressed 
post-ACS patients is associated with the decreased release of platelet/endothelial biom- 
arkers. Mild antiplatelet properties of SSRI's may represent an attractive additional 
advantage for using these agents in patients with depression in the context of coronary 
artery disease and ischemic stroke. 
1027-42 The Association of Isosorbide-5-Monitrate to an ACE 
Inh ib i tor  Started Ear ly  Af ter  Myocardial Infarction 
Improves Left Ventricular Structure and Function Over 
Three Months: The Delepril and Remodelling in Acute 
Myocardial Infarction (DRAMI) Study 
Roberto Latini, Aldo P. Maggioni, Lidia Staszewskv. Violeta Labarta, Paolo Marino, 
Giovanni Cremonesi, Silvana Gramenzi, Giuseppe Sarcina, Sergio Piras, for the DRAMI 
Investigators,/stituto Mario Negri, Mi/ano, /taly, Centro Studi ANMCO, Firenze, Italy. 
Background. ACE inhibitor (ACEi) started early after AMI reduce moda~ity and morbidity. 
A subanalysis of the GISSi-3 study suggested additional benefit when a nitrate was 
associated to the ACEL DRAMI was a multicenter, randomised, double-blind study to (1) 
verify whether isosorbide-5-mononitrate (ISSMN) added to an ACEi enhances its benefi- 
cial effects on LV remodelling, and (2) assess the tolerability of a new ACEi, delapril (D), 
in comparison to lisinopril (L). 
Methods. 177 patients were randomised to D or L, with IS5MN or placabo (4 groups) 
within the first 36h of AMI symptoms, if they had at least 7 abnormal ECG leads and/or 
signs and symptoms of LV dysfunction, in absence of contraiodications. Study drugs 
were given for 3 mos, serial echocardiographic (echo) exams were done at the site and 
read by a core lab. 
Results. At randomization, 37% of the pts were in Killip class II and III, 81% received 
thrombolytics, 91% aspirin, 43% betablockers, 3-too incidence of the primary combined 
endpoint of mortality and serious clinical events was 38.4% and 31.9% in D and L (p=NS) 
and 35.6% and 35.5% in IS5MN and placebo, 3-mo mortality was 10.2%, without differ- 
ence between treatments. Mean (+/-SD) differences between 3-mo echo and baseline 
(D) are shown in the table. 
Conclusion. The systematic association of IS5MN to an ACEi significantly improves LV 
structure and function after AMI vs ACEi+placebo, without an excess of adverse reac- 
tions. 3-mo treatment with D or L is well tolerated when started within the first 36h after 
AMI. 
IS5MN placebo p (Wilcoxon) 
end diastolic vol 4.2±29.4 17.4±33.5 0.04 
end systolic vol -5.5±19.3 7.5±26.1 0.005 
ejection fraction 6.7¢8.2 1.9±8.8 0.01 
1027-43 Stroke Reduct ion  With Low-Medium Dose Warfar in/  
Aspirin Combination Following Myocardial Infarction in 
the CHAMP Study 
Jonathan F. Plehn. Ayumi K. Shintani, Michael D. Ezekowitz, Peter N. Peduzzi, Peter S. 
Rahko, Louis D. Flora, for the CHAMP Investigators, SL Francis Hospital, Roslyn, New 
York. 
Background: Following myocardial infarction (MI), 5,059 subjects (99% male, mean 
age=62 +10 years) were randomly assigned to either: a) warfarin and 81 mg/day of aspi- 
rin (WAR) with a target INR=1.5-2.5 or b) aspirin 162 mg/day alone (ASA) in the VA Com- 
bination Hemotherapy and Mortality Prevention (CHAMP) Study. As previously reported, 
all-cause mortality and MI recurrence were unaffected by treatment over a median fol- 
Iowup of 36 months. Because the value of routine, low-moderate l vel anticoagulation i
stroke prevention following MI has been controversial, we assessed the effect of WAR on 
stroke incidence in CHAMP. 
Results: By intention to treat analysis, subjects randomized to WAR had stroke inci- 
dence similar to ASA at 6, 12 or 36 months as indicated by relative risks (RR) and 95% 
confidence intervals (CI) which were non-significant (RR=0.91, CI 0.55, 0.91; RR=1.0, CI 
0.65,1.55; RR=0.89, CI 0.66-1.21, respectively). However, in on-traatment analysis, 
when stratified by lower and higher INRs (LWAR=<2.0, HWAR=>2.0 ), WAR had signifi- 
cant protective and apparent dose-ranging effects. Compared to ASA (n=2,537), LWAR 
subiects (n=1,301) with mean INR at 6 months=l.5 ± 0.3 experienced 2, 8 and 29 
strokes at 6, 12 and 36 months, respectively (RR=0.12, CI 0.03,0.50; RR=0.37, CI 
0.17,0.78; RR=0.60, CI 0.39,0.91) while HWAR (n=416) with mean INR =2.4+0.5 had 0 
strokes at 6 and 12 months (RR=0.0, CI 0,0 for both) and 5 strokes at 36 months 
(RR=0.33, CI 0.14,0.82) with first stroke occurrence at 401 days following randomization. 
Stroke incidence or treatment effect was unrelated to either ECG MI location (anterior/ 
septal vs. other MIs) or qualitative echo ejection fraction. 
Conclusions:l) By on-treatment analysis, low-medium dose warfarin/aspirin combina- 
tion significantly reduced stroke incidence compared to aspirin throughout he study 
duration, 2) Stroke reduction associated with WAR was greater when INR=_> 2.0 and was 
independent of infarct location or ventricular systolic function. 
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1027-44 Female Gender Does Not Impact Outcomes in Patients 
With Postinfarct Left Ventricular Dysfunction Treated 
With Carvedilol 
Willem J. Remme. Henry J. Dargie, lan Ford, Jose-Luis Lopez Sendon, Norman Sharpe, 
Antje Blank, on behalf of the CAPRICORN Investigators, Sticares Foundation, 
Rotterdam, The Netherlands. 
Background: CAPRICORN, a randomised double blind placebo-controlled study of 
carvedilol in patients with left vantricular dysfunction after myocardial infarction on ACE 
inhibition, demonstrated improvement in survival, non-fatal MI and in the combined end- 
point of cardiovascular mortality or non-fatal MI or hospitalisation for heart failure. 
Although conflicting, previous heart failure trials have suggested a sex/beta-blocker inter- 
action. This abstract aims to determine whether gender differences impact on the effects 
of carvedilol in CAPRICORN. Methods: 1959 patients with acute MI and an LV ejection 
fraction <= 40 % were included in 163 centres in 17 countries. 259 women and 716 men 
were randomised to carvedilo] and 260 and 724 respectively to placebo. Carvedilol did 
not affect withdrawal rates in either sex. Analyses were done on ITT basis and for time to 
first event. Mean follow-up was 1.3 years. Results: In women carvedilol reduced all- 
cause mortality by 27 %, HR 0.73 (95 % CI 0.49-1.09) and in men by 22 %, HR 0.78 
(0.58-1.06). The second co-primary endpoint all-cause mortality or cardiovascular hospi- 
talisations was reduced in women by 17 %, HR 0.83 (0.63-1.08) and in men by 3 %, HR 
0.97 (0.81-1.t5). All cause mortality or non-fatal MI was reduced by 32 % (0.46-0.98) in 
women and by 27 % (0.56-0.95) in men. Non-fatal MI was reduced by 25 % (0.34-1.66) 
in women and by 47 % (0.32-0.88) in men, whereas the combined endpoint of CV death 
or non-fatal MI or hospitalisation for heart failure decreased by 15 % (0.62-1.17) in 
women vs 21% (0.63-0.98) in men. Hospitalisation for heart failure fell by 11% (0.58- 
1.37) in women and by 16 % (0.62-1.13) in men. Interaction p values were all non signifi- 
cant. Conclusion: The analysed mortality and morbidity endpoints confirm that 
carvedilol had comparable effects in women and in men. Although women were under- 
represented as in most large scale trials, the consistent findings suggest a uniform pro- 
tective role for carvedilol irrespective of gender. 
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1049-31 Effects of Losartan and Quinapril on Myocardial Infarct 
Size and Endothelial Function 
Booino Zhu. Richard E. Sievers, Amanda E. Browne, Randall J. Lee, Kanu Chattejee, 
William Grossman, William W. Parmley, University of California, San Francisco, San 
Francisco, Cafifomia. 
Background:We previously showed that the angiotensin II receptor blocker Iosartan 
reduced infarct size and arrhythmias in a rat model of ischemia-raperfusion. The angio- 
tensin converting enzyme inhibitor quinapril has a strong affinity for tissue. We evaluated 
the individual and combined effects of Iosartan (L) and quinapril (Q) in a rat model of 
ischemia-repeffusion. Methods: Eighty Sprague-Dawley rats were randomized into 4 
groups: one control (C) and three pretreatment groups (L,Q,LQ) which were given 40 rag/ 
kg/day of Iosartan or/and 2.4 mg/kg/day of quinapri] in drinking water for 6 weeks respec- 
tively. After pretreatment, rats were subjected to 17 rain of LAD occlusion and 120 rain of 
reperfusion with hemodynamic and ECG monitoring. Results: Hemodynamic changes 
were the same, except group LQ had lower blood pressure. Effective refractory period 
(ERP) in the 4 groups were similar. Ventdcular fibrillation threshold (VFT) in the three pre- 
treatment groups was higher than controls. VF episodes per rat in the three pretreatmant 
groups were lower than controls. Infarct size was significantly reduced by Iosartan and 
Iosartan plus quinapril. Calcium ionophore (A23187) induced endothelium-dependent 
maximum vasorelaxation (Vasorelax) in groups L and LQ was higher than controls. Con- 
clusions: Six weeks of pretreatment with Iosartan and/or quinapril reduced arrbythmias; 
Iosartan or Iosartan plus quinapril decreased infarct size and increased endothelium- 
dependent vasorelaxation. 
(*P<O.05, **P<O.Ol when compared with the control group) 
Groups VFT(mA) VF Episodes infarct size(%) Vasorelax(%) 
Control (C) 0.36±0.05 2.4±0.2 43±4 -50±7 
Losartan (L) 1.27±0.25" 1.6±0.3* 30±6* -68±9" 
Quinapril (Q) 1.23±0.19" 1.1±0.3"* 43±3 -64±6 
Losartan+Quinapril (LQ) 1.29±0.39* 0.5±0.2** 30±4* -70±6" 
